AstraZeneca and The University of Texas M. D. Anderson Cancer Center have entered into scientific collaboration agreements that will allow for integrated preclinical and clinical research on new treatments for cancer, focusing initially on aerodigestive diseases (e.g., lung cancer, head and neck cancers or colorectal cancers). Under the terms of the collaboration, these renewable, three-year, master agreements allow for variety of initiatives across a range of AstraZeneca oncology products ...